FLUID COMPATIBILITY CHART for metal threaded fittings sealed with Loctite® Sealants LIQUIDS, SOLUTIONS & SUSPENSIONS
Loctite product numbers in red are worldwide or application-specific products(This is a list of chemical stability only. It does not constitute approval for use in the processing of food, drugs, cosmetics, pharmaceuticals, andingestible chemicals.) Loctite® sealants are not recommended for use in pure oxygen or chlorine environments or in conjunction with strongoxidizing agents, an explosive reaction can result. FLUID COMPATIBILITY CHART for metal threaded fittings sealed with Loctite® Sealants LIQUIDS, SOLUTIONS & SUSPENSIONS
Compatible Including #242®, 243,542, 545, 565, 567, 569, 571, 572,
NOTE: 1. The above information does not constitute a recommendation of sealant use. It is intended only as a guide for consideration by the purchaser with the expectation of favorable confirming
test results. It is impossible to test sealant reaction with the multitude of chemicals in existence, therefore, compatibility has been estimated based on a wide variety of customer experience. 2. With the stringent action of such chemicals as Freon, strong cold acids and caustics, thorough evaluation is suggested. Sealing of hot corrosive chemicals is not recommended. 3. Contact Loctite Corporation for use with chemicals not covered by this information.
§Listing(s) may be Brand Name(s) or Trademarks for chemicals of Corporations other than Loctite.
Loctite product numbers in red are worldwide or application-specific products.
(This is a list of chemical stability only. It does not constitute approval for use in the processing of foods, drugs, cosmetics, pharmaceuticals, and ingestiblechemicals). Loctite® sealants are not recommended for use in pure oxygen or chlorine environments or in conjunction with strong oxidizing agents, an explosivereaction can result. Loctite Industrial
The data contained herein are furnished for information only and are believed to be
CORPORATION SPECIFICALLY DISCLAIMS ANY LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL
reliable. We cannot assume responsibility for the results obtained by others over whose
DAMAGES OF ANY KIND, INCLUDING LOST PROFITS. The discussion herein of various processes
methods we have no control. It is the user's responsibility to determine suitability for the
or compositions is not to be interpreted as a representation that they are free from domination
user's purpose of any production methods mentioned herein and to adopt such precautions
of patents owned by others or as a license under any LOCTITE CORPORATION patents which
as may be advisable for the protection of property and of persons against any hazards
may cover such processes or compositions. We recommend that each prospective user test the
that may be involved in the handling and use thereof.
proposed application to determine its suitability for the purposes intended prior to incorporation
In light of the foregoing, LOCTITE CORPORATION SPECIFICALLY DISCLAIMS ALL
to determine its suitability for manufacturing process using this data as a guide. This product
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
may be covered by one or more United States or foreign patents or patent application.
ARISING FROM SALE OR USE OF LOCTITE CORPORATION'S PRODUCTS. LOCTITE
Loctite, 242, and 271 are trademarks of Loctite Corporation, U.S.A. Copyright 2002. Loctite Corporation. All rights reserved. 335/LT-836B (3/02)
FACILITIES AND EQUIPMENT The GIS Training and Research Center (GIS TReC) at Idaho State University maintains a staff of personnel with knowledge, skills, and abilities across a wide spectrum of Geographic Information Science. The University's GIS Director and team leader of the GIS TReC, Keith T. Weber is a Certified GIS Professional (GISP) with over 35 peer-reviewed professional publicatio
COGENTUS PHARMACEUTICALS BEGINS CLINICAL STUDY TO CONFIRM THE FULL ANTIPLATELET BENEFIT OF NEW COMBINATION MEDICINE CGT-2168 MENLO PARK, CA (Jan. 16, 2008) -- Cogentus Pharmaceuticals, Inc. today announced that dosing has begun in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168. CGT-2168 is a once-daily capsule that combines